CN117695327A - Abelmoschus manihot compound anti-inflammatory lung-heat-clearing traditional Chinese medicine and preparation method thereof - Google Patents
Abelmoschus manihot compound anti-inflammatory lung-heat-clearing traditional Chinese medicine and preparation method thereof Download PDFInfo
- Publication number
- CN117695327A CN117695327A CN202311836548.5A CN202311836548A CN117695327A CN 117695327 A CN117695327 A CN 117695327A CN 202311836548 A CN202311836548 A CN 202311836548A CN 117695327 A CN117695327 A CN 117695327A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- traditional chinese
- compound
- heat
- abelmoschus manihot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 240000005959 Abelmoschus manihot Species 0.000 title claims abstract description 39
- 235000001075 Abelmoschus manihot Nutrition 0.000 title claims abstract description 39
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000004054 inflammatory process Effects 0.000 claims abstract description 24
- 206010061218 Inflammation Diseases 0.000 claims abstract description 23
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 18
- 241000628997 Flos Species 0.000 claims abstract description 18
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 235000006533 astragalus Nutrition 0.000 claims abstract description 16
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 16
- 235000011477 liquorice Nutrition 0.000 claims abstract description 14
- 235000005739 manihot Nutrition 0.000 claims abstract description 12
- 210000004072 lung Anatomy 0.000 claims abstract description 10
- 241001061264 Astragalus Species 0.000 claims abstract description 8
- 210000004233 talus Anatomy 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims description 46
- 239000000463 material Substances 0.000 claims description 26
- 239000000284 extract Substances 0.000 claims description 21
- 238000001035 drying Methods 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 14
- 240000003183 Manihot esculenta Species 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 241000045403 Astragalus propinquus Species 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 239000004375 Dextrin Substances 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 239000009636 Huang Qi Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 13
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 abstract description 8
- 206010035664 Pneumonia Diseases 0.000 abstract description 8
- 241000700605 Viruses Species 0.000 abstract description 7
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract description 6
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 abstract description 5
- 230000001276 controlling effect Effects 0.000 abstract description 5
- 229930003935 flavonoid Natural products 0.000 abstract description 5
- 235000017173 flavonoids Nutrition 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 abstract description 5
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 abstract description 5
- 241000721047 Danaus plexippus Species 0.000 abstract description 4
- 230000002458 infectious effect Effects 0.000 abstract description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract description 4
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 abstract description 3
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 abstract description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract description 3
- -1 flavonoid compounds Chemical class 0.000 abstract description 3
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 abstract description 3
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 abstract description 3
- 235000007743 myricetin Nutrition 0.000 abstract description 3
- 229940116852 myricetin Drugs 0.000 abstract description 3
- 235000005875 quercetin Nutrition 0.000 abstract description 3
- 229960001285 quercetin Drugs 0.000 abstract description 3
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 abstract description 3
- 230000000840 anti-viral effect Effects 0.000 abstract description 2
- 230000000295 complement effect Effects 0.000 abstract description 2
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000221022 Manihot Species 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 238000004806 packaging method and process Methods 0.000 description 18
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 238000000605 extraction Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 238000005086 pumping Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 241000219071 Malvaceae Species 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010047924 Wheezing Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 229930194248 Licoflavone Natural products 0.000 description 2
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940069445 licorice extract Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241001075517 Abelmoschus Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000011948 Multi-organ disease Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000011492 sheep wool Substances 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, in particular to an abelmoschus manihot compound anti-inflammatory lung-heat-clearing traditional Chinese medicine and a preparation method thereof, wherein the abelmoschus manihot compound anti-inflammatory lung-heat-clearing traditional Chinese medicine comprises the following raw materials of abelmoschus manihot, honeysuckle, rhizoma atractylodis, astragalus and liquorice; the components of the abelmoschus manihot compound traditional Chinese medicine for resisting inflammation and clearing lung have complementary effects, and can synergistically exert the efficacy; the flos Abelmoschi Manihot is used as a monarch drug, and is rich in flavonoid compounds including hyperoside, isoquercitrin, myricetin, quercetin and other effective components, and the components have remarkable antiviral and anti-inflammatory effects; therefore, the medicine of the invention not only can be used for treating and preventing pneumonia, but also can be used for preventing, controlling and preventing other broad-spectrum infectious viruses.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to an abelmoschus manihot compound traditional Chinese medicine for resisting inflammation and clearing lung and a preparation method thereof.
Background
Pneumonia refers to inflammation of lung tissue, which may be caused by a variety of causes, including infection by bacteria, viruses, fungi or other microorganisms, and possibly by inhalation of chemicals or other substances, with the most common type of pneumonia being infectious pneumonia caused by bacteria or viruses.
The general treatment for infectious pneumonia is administration of antibiotics or antiviral drugs, which, although effective in treating a specific type of pneumonia, have some disadvantages and limitations. For example, bacteria may develop resistance to antibiotics or antiviral drugs over time. As another example, antiviral drugs and antibiotics are not generally broad spectrum and their pharmaceutical effectiveness may be limited.
Traditional Chinese medicine is usually a compound medicine composed of a plurality of natural plants, animals or minerals, one traditional Chinese medicine prescription may contain a plurality of compounds, each compound may act on different biological targets to generate various effects, and then the traditional Chinese medicine has a certain broad spectrum.
Therefore, the novel anti-inflammatory lung-heat clearing traditional Chinese medicine has important significance in improving respiratory system health, coping with inflammatory diseases, improving immunity and the like.
Disclosure of Invention
The invention provides a compound anti-inflammatory lung-heat-clearing traditional Chinese medicine of abelmoschus manihot, which comprises the following raw materials:
abelmoschus manihot, honeysuckle, rhizoma atractylodis, astragalus mongholicus and liquorice.
Preferably, the mass portion ratio of the abelmoschus manihot, the honeysuckle, the rhizoma atractylodis, the astragalus and the liquorice is 5-7:2-2.5:2-2.5:1-1.5:1-1.5.
Preferably, the preparation method of the abelmoschus manihot compound traditional Chinese medicine for resisting inflammation and clearing lung comprises the following steps:
mixing the abelmoschus manihot, honeysuckle, rhizoma atractylodis, astragalus mongholicus and liquorice with a solvent, and extracting to obtain an extracting solution;
concentrating the extracting solution to obtain concentrated solution;
drying the concentrated solution to obtain extract dry powder;
mixing the extract dry powder with auxiliary materials and adhesive, and granulating to obtain wet granules;
and drying the wet granules to obtain dried granules, wherein the dried granules are the abelmoschus manihot compound traditional Chinese medicine for resisting inflammation and clearing lung.
Preferably, the density of the concentrate is 1.1-1.2.
Preferably, the moisture content of the dried granules is less than 5%.
Preferably, the auxiliary materials are dextrin and lactose.
Preferably, when the flos Abelmoschi Manihot, flos Lonicerae, rhizoma Atractylodis, radix astragali, and Glycyrrhrizae radix are mixed with solvent and extracted, the method comprises:
mixing the flos Abelmoschi Manihot, flos Lonicerae, rhizoma Atractylodis, radix astragali, glycyrrhrizae radix with solvent, heating with steam, and maintaining at 60-100deg.C for 1-2 hr to obtain the extractive solution.
Preferably, the addition amount of the solvent is 8-10 times of the total weight of the abelmoschus manihot, the honeysuckle, the rhizoma atractylodis, the astragalus and the liquorice.
Preferably, the solvent is water or alcohol.
Preferably, the concentration of the alcohol is 40-80%.
More preferably, the concentration of alcohol is 55-75%.
The invention provides an abelmoschus manihot compound traditional Chinese medicine for resisting inflammation and clearing lung, which has the beneficial effects that compared with the prior art:
the abelmoschus manihot compound anti-inflammatory lung-heat clearing traditional Chinese medicine is a plant extract compound preparation with scientific proportion, aims at improving immunity of wide crowds, enhancing resistance and has the effects of resisting viruses, resisting inflammation and clearing lung. The medicine takes the traditional Chinese medicinal materials such as the abelmoschus manihot, the honeysuckle, the rhizoma atractylodis, the astragalus mongholicus, the liquorice and the like as main components, and the components have complementary effects and can synergistically exert the efficacy. The flos Abelmoschi Manihot is used as a monarch drug, and is rich in flavonoid compounds including hyperoside, isoquercitrin, myricetin, quercetin and other effective components, and the components have remarkable antiviral and anti-inflammatory effects. Therefore, the medicine of the invention not only can be used for treating and preventing pneumonia, but also can be used for preventing, controlling and preventing other broad-spectrum infectious viruses.
The uniqueness and efficacy of the abelmoschus manihot compound traditional Chinese medicine for resisting inflammation and clearing lung can form good complementarity with similar medicines in the existing market.
Detailed Description
The following description of the technical solutions in the embodiments of the present invention will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
According to the principle of compatibility of monarch, minister, assistant and guide:
1. abelmoschus manihot flower is a monarch drug (60%)
Abelmoschus manihot (Abelmoschus Manihot) is an annual herb of Abelmoschus genus of Malvaceae (Malvaceae). The traditional Chinese medicine is mainly used as flos Abelmoschi Manihot for treating the traditional Chinese medicine, has sweet and cold taste, and has the functions of clearing heat, promoting diuresis, relieving swelling, removing toxin and the like.
1.1 pharmacological action of Abelmoschus manihot
The main chemical components in the flower of abelmoschus manihot are flavonoids, organic acids, tannins, long-chain hydrocarbons and other compounds reported in literature. Modern pharmacological researches show that the flavonoid component of the abelmoschus manihot has the effects of protecting heart and brain ischemia, improving kidney function, repairing oral mucosa ulcer and the like, can treat various oral inflammations, chronic bronchitis and has remarkable pain relieving effect.
Hyperin (English name: hyperside) in flavonoids is derived from dry flower of Abelmoschus manihot L.of Malvaceae, and has the characteristics: pale yellow crystalline powder; slight smell and no bitter taste. Has various physiological activities such as anti-inflammatory, spasmolytic, diuretic, cough relieving, blood pressure reducing, cholesterol reducing, protein assimilation, local and central pain relieving, heart and cerebral vessel protecting effects, etc., and is an important natural product. Hyperin has remarkable local analgesic effect, has no dependence, and is a novel local analgesic raw material;
1.2 hyperin has obvious anti-inflammatory effect
After the rats are implanted with the sheep wool balls, 20mg/Kg of the rats are intraperitoneally injected for 7 days every day, so that the inflammatory process is obviously inhibited.
1.3 has a stronger cough relieving effect
Effective components such as isoquercitrin, myricetin, quercetin and the like have the effects of regulating human endocrine and improving human immunity, enhancing resistance, resisting virus, resisting bacteria, resisting inflammation, clearing lung-heat, relieving cough and the like (a great deal of scientific literature and arguments).
2. Honeysuckle and rhizoma atractylodis are ministerial drugs (each accounting for 20 percent):
2.1 honeysuckle flower
Cold in nature, sweet in taste, entering the lung, heart and stomach meridians, has the effects of clearing heat and detoxicating, resisting inflammation, tonifying deficiency and treating wind, and is mainly used for treating distending and fullness diseases, warm diseases and fever, carbuncles and ulcers due to heat toxin, tumors and the like. It has therapeutic effects on dizziness, thirst, hyperhidrosis, vexation, enteritis, bacillary dysentery, measles, pneumonia, epidemic encephalitis, acute mastitis, septicemia, appendicitis, skin infection, carbuncle, furuncle, erysipelas, parotitis, suppurative tonsillitis, etc.
Honeysuckle has been known for its wide medicinal value since ancient times. The efficacy of the traditional Chinese medicine is mainly clearing heat and detoxicating, and mainly treating warm diseases and fever, heat toxin and bloody dysentery, carbuncles and furunculosis, and the like. Modern researches have proved that honeysuckle contains chlorogenic acid, luteolin glycoside and other pharmacologically active components, and has strong inhibitory effect on various pathogenic bacteria such as hemolytic streptococcus and staphylococcus aureus and pathogenic viruses of upper respiratory tract infection.
2.2 rhizoma Atractylodis
Non-toxic; spleen, stomach and liver channels;
efficacy: eliminating dampness, strengthening spleen, dispelling pathogenic wind, dispelling cold, and improving eyesight;
the main indications are: can be used for treating damp obstruction of middle energizer, abdominal distention, diarrhea, edema, tinea pedis, rheumatalgia, common cold due to wind-cold, night blindness, and dim eyesight.
The usage amount is as follows: decoct 3-9 g.
3. Astragalus membranaceus is an adjuvant drug (10%)
Radix astragali has sweet taste and slightly warm nature, and has effects of invigorating qi, consolidating superficial resistance, promoting urination, tonifying heart, lowering blood pressure, resisting bacteria, removing toxic substances, expelling pus, promoting granulation, enhancing capillary resistance, and inhibiting sweat and sex hormone, and can be used for treating spontaneous perspiration due to exterior deficiency, qi deficiency, internal injury, spleen deficiency diarrhea, edema, and carbuncle.
Modern medical research shows that astragalus has the functions of enhancing the immunity of organisms, protecting liver, promoting urination, resisting aging and stress, reducing blood pressure and resisting bacteria widely.
4. Glycyrrhrizae radix as a guiding drug (10%)
Licorice root, radix Glycyrrhizae is sweet in smell, flat and nontoxic. Can be used for treating carbuncle, sore, and sore throat. It can be used singly, orally taken or externally applied or combined. It is also combined with cough due to wind-heat, cough due to wind-cold and cough due to heat-phlegm. The licoflavone, the licorice extract and the glycyrrhetinic acid all have obvious antitussive effect; the phlegm eliminating effect is also obvious, and the effect intensity is glycyrrhizic acid > licoflavone > licorice extract.
Can be used for treating asthma and cough; other medicinal applications such as Erchen decoction for treating cough due to damp-phlegm can be also combined; poria cocos, radix schisandrae chinensis, ginger and spice soup for treating cold phlegm cough and asthma; sang Xingshang for treating cough with dry phlegm; radix platycodi soup for treating lung abscess, cough, saliva, stink and purulent phlegm caused by heat toxin; licorice and dried ginger decoction for treating cough and saliva.
Glycyrrhrizae radix also has antiinflammatory and antiallergic effects, and can protect inflamed throat and airway mucosa. Glycyrrhiza extract and glycyrrhizic acid have glucuronic acid-like detoxification effect on some toxicants.
Example 1
A preparation method of flos Abelmoschi Manihot compound traditional Chinese medicine for resisting inflammation and clearing lung-heat comprises the following steps:
1. raw material selection: selecting materials of flos Abelmoschi Manihot, flos Lonicerae, rhizoma Atractylodis, radix astragali and Glycyrrhrizae radix;
2. weighing: weighing the Chinese medicinal materials according to the formula, and uniformly mixing; wherein, the weight part ratio of the abelmoschus manihot, the honeysuckle, the rhizoma atractylodis, the astragalus and the liquorice is 5:2:2:1:1.
3. extracting: adding the mixed medicinal materials into a multifunctional extraction tank, and adding 8 times of solvent which is edible alcohol; wherein the edible alcohol concentration is 40%.
Introducing steam into the multifunctional extraction tank for heating, keeping the temperature in the multifunctional extraction tank at 60deg.C, maintaining the temperature for 1hr, cooling to 45deg.C, and opening the discharge valve to discharge the medicinal liquid into the storage tank. Adding solvent 8 times of the weight of the dry medicinal materials into the multifunctional extraction tank, extracting for the second time according to the method, filtering the medicinal liquid to obtain an extract, and placing the extract into a storage tank.
4. Vacuum concentration: pumping the extract into a concentrator, vacuumizing, maintaining the temperature at 50 ℃ for vacuum concentration, and concentrating the liquid medicine to the density of 1.1 to obtain a concentrated solution.
5. Spray drying: pumping the concentrated solution into a dryer for drying to obtain extract dry powder.
6. Mixing and granulating: mixing a certain amount of extract dry powder with a certain amount of adjuvant and binder, granulating to obtain wet granule, wherein the adjuvant is dextrin and lactose, and the binder is syrup (sucrose). The total weight of the auxiliary materials and the adhesive is 5% of the dry extract powder, and the weight ratio of the auxiliary materials to the adhesive is 1:2, the weight ratio of dextrin to lactose is 10:5.
7. and (3) drying: and (3) drying the wet particles in a drying oven to obtain dried particles, and controlling the moisture content of the dried particles to be less than 5%.
8. And (3) particle packaging: and (5) placing the dried granules into a granule packaging machine for subpackaging, thus obtaining the finished product of the granule.
9. Particle packaging or tabletting: the granule packaging is to put the dried granules into a granule packaging machine for subpackaging, thus obtaining a granule finished product; tabletting is to put the dried granules into a V-shaped mixer, add lubricant and mix for 15 seconds, and transfer the mixture into a tablet press to carry out tabletting, thus obtaining the finished tablet. And (5) packaging the finished granules or tablets after the finished granules or tablets are qualified.
Example 2
A preparation method of flos Abelmoschi Manihot compound traditional Chinese medicine for resisting inflammation and clearing lung-heat comprises the following steps:
1. raw material selection: selecting materials of flos Abelmoschi Manihot, flos Lonicerae, rhizoma Atractylodis, radix astragali and Glycyrrhrizae radix;
2. weighing: weighing the Chinese medicinal materials according to the formula, and uniformly mixing; wherein, the weight part ratio of the abelmoschus manihot, the honeysuckle, the rhizoma atractylodis, the astragalus and the liquorice is 7:2.5:2.5:1.5:1.5.
3. extracting: adding the mixed medicinal materials into a multifunctional extraction tank, and adding 10 times of solvent which is edible alcohol; wherein the edible alcohol concentration is 80%.
Introducing steam into the multifunctional extraction tank for heating, keeping the temperature in the multifunctional extraction tank at 100deg.C, maintaining the temperature for 2hr, cooling to 55deg.C, and opening the discharge valve to discharge the medicinal liquid into the storage tank. Adding solvent 10 times of the weight of the dry medicinal materials into the multifunctional extraction tank, extracting for the second time according to the method, filtering the medicinal liquid to obtain extract, and placing into a storage tank.
4. Vacuum concentration: pumping the extract into a concentrator, vacuumizing, maintaining the temperature at 75 ℃ for vacuum concentration, and concentrating the liquid medicine to the density of 1.2 to obtain a concentrated solution.
5. Spray drying: pumping the concentrated solution into a dryer for drying to obtain extract dry powder.
6. Mixing and granulating: mixing a certain amount of extract dry powder with a certain amount of adjuvant and binder, granulating to obtain wet granule, wherein the adjuvant is dextrin and lactose, and the binder is syrup (sucrose). The total weight of the auxiliary materials and the adhesive is 10% of the dry extract powder, and the weight ratio of the auxiliary materials to the adhesive is 2:1, the weight ratio of dextrin to lactose is 10:6.
7. and (3) drying: and (3) drying the wet particles in a drying oven to obtain dried particles, and controlling the moisture content of the dried particles to be less than 5%.
8. And (3) particle packaging: and (5) placing the dried granules into a granule packaging machine for subpackaging, thus obtaining the finished product of the granule.
9. Particle packaging or tabletting: the granule packaging is to put the dried granules into a granule packaging machine for subpackaging, thus obtaining a granule finished product; tabletting is to put the dried granules into a V-shaped mixer, add lubricant and mix for 30 seconds, and transfer the mixture into a tablet press to carry out tabletting, thus obtaining the finished tablet. And (5) packaging the finished granules or tablets after the finished granules or tablets are qualified.
Example 3
A preparation method of flos Abelmoschi Manihot compound traditional Chinese medicine for resisting inflammation and clearing lung-heat comprises the following steps:
1. raw material selection: selecting materials of flos Abelmoschi Manihot, flos Lonicerae, rhizoma Atractylodis, radix astragali and Glycyrrhrizae radix;
2. weighing: weighing the Chinese medicinal materials according to the formula, and uniformly mixing; wherein, the weight part ratio of the abelmoschus manihot, the honeysuckle, the rhizoma atractylodis, the astragalus and the liquorice is 6:2:2:1:1.
3. extracting: adding the mixed medicinal materials into a multifunctional extraction tank, and adding 9 times of solvent which is water.
Introducing steam into the multifunctional extraction tank for heating, keeping the temperature in the multifunctional extraction tank at 80deg.C, maintaining the temperature for 1.5hr, cooling to 50deg.C, and opening the material valve to discharge the medicinal liquid into the storage tank. Adding solvent 9 times of the dry medicinal material weight into the multifunctional extraction tank, extracting for the second time according to the method, filtering the medicinal liquid to obtain extractive solution, and placing into a storage tank.
4. Vacuum concentration: pumping the extract into a concentrator, vacuumizing, maintaining at 60deg.C, vacuum concentrating, and concentrating the medicinal liquid to density of 1.1 to obtain concentrated solution.
5. Spray drying: pumping the concentrated solution into a dryer for drying to obtain extract dry powder.
6. Mixing and granulating: mixing a certain amount of extract dry powder with a certain amount of adjuvant and binder, granulating to obtain wet granule, wherein the adjuvant is dextrin and lactose, and the binder is syrup (sucrose). The total weight of the auxiliary materials and the adhesive is 9% of the dry extract powder, and the weight ratio of the auxiliary materials to the adhesive is 2:1, the weight ratio of dextrin to lactose is 10:5.
7. and (3) drying: and (3) drying the wet particles in a drying oven to obtain dried particles, and controlling the moisture content of the dried particles to be less than 5%.
8. And (3) particle packaging: and (5) placing the dried granules into a granule packaging machine for subpackaging, thus obtaining the finished product of the granule.
9. Particle packaging or tabletting: the granule packaging is to put the dried granules into a granule packaging machine for subpackaging, thus obtaining a granule finished product; tabletting is to put the dried granules into a V-shaped mixer, add lubricant and mix for 25 seconds, and transfer the mixture into a tablet press to carry out tabletting, thus obtaining the finished tablet. And (5) packaging the finished granules or tablets after the finished granules or tablets are qualified.
Test examples
Of the 100 patients observed, the proportion of men and women was comparable, each 50. Their ages are all between 35 and 60 years. The time span from onset to visit varies from 2 to 10 days. The course of disease is mainly concentrated on 2-4 days, 45 cases are all considered; 32 patients with the disease course of 5-8 days; there were 23 patients with 9-10 days of disease course. These patients all showed symptoms of cough, fever, wheezing, dyspnea, etc. to varying degrees.
We observed the therapeutic effect of 100 patients taking the finished granules of example 3, with 100 patients in clinical response without adverse effects during the treatment period. All patients took the drug at a dose of three times daily for three days. Statistics show that 71 patients have significant treatment effects, 26 patients are effective, and only 3 patients are not significantly improved. Therefore, the total effective rate of the medicine is 97%.
Typical cases:
case 1: patient a,42 year old female, visits the third day after onset and seven days after the course of the disease. The main symptoms include cough, fever and slight wheezing. The patient follows the order and takes the finished granule of example 3 three times a day for three days. During the treatment period, the symptoms of the patients are obviously improved, the cough is relieved, the fever is relieved, and the borborygmus is reduced. After the treatment is finished, the patient is completely recovered, and the treatment effect is obvious.
Case 2: patient B, a 38 year old male, visits six days after onset and nine days after the course of the disease. The main symptoms include persistent cough, high fever and significant dyspnea. The patient received the finished granule treatment of example 3 three times daily for three days. During the treatment process, the patient breathes steadily, coughs are weakened, and the body temperature is reduced. After the treatment is finished, the patient is obviously improved, and the treatment effect is effective.
Case 3: patient C,50 year old female, visits six days after onset and ten days after the course of the disease. The main symptoms include intractable cough, high fever and severe wheezing. The patient received the finished granule treatment of example 3 three times daily for three days. During the treatment period, the symptoms of the patient are relieved, the cough is relieved, and the body temperature is reduced. After the treatment is completed, the condition of the patient does not reach the standard of complete rehabilitation, but is obviously improved compared with the condition before the treatment, and the overall treatment effect is basically good.
In summary, the compound anti-inflammatory lung-heat-clearing traditional Chinese medicine for abelmoschus manihot disclosed by the invention has the technical effects that:
1. based on the special concentrated research and development of the Chinese medicinal materials of the abelmoschus manihot for many years, the Chinese medicinal materials of the invention have originality and uniqueness, are basically medicinal and edible plants, have no toxic and side effects recorded in history, have strong stability, pertinence and synergy, are safe and effective, and are multifunctional and personalized therapeutic medicaments capable of meeting the requirements of different consumers on prevention, health care, treatment and rehabilitation.
2. Innovative: the traditional Chinese medicine and the prescription thereof are resource treasures for finding new medicines, combine the original thinking of the traditional Chinese medicine with the modern medicine technology, keep the rule and the characteristics of the compatibility of the traditional Chinese medicine prescription and develop the innovative traditional Chinese medicine. The invention is based on the theory of traditional Chinese medicine, follows the compatibility theory and principle of traditional Chinese medicine prescription, and innovates and constitutes the modern traditional Chinese medicine preparation through the classification extraction of the effective components of the compatible traditional Chinese medicine and the compatibility of the effective parts. The medicine has the advantages of basically definite medicinal effect substances, relatively clear action mechanism, relatively definite clinical adaptation diseases, relatively strong pertinence, safety, effectiveness, controllable quality and suitability for industrialized popularization.
3. The characteristics and advantages are that: the invention is based on the traditional Chinese medicine with safe and effective clinical application, is suitable for the process technology and quality standard of the modern manufacturing industry, is suitable for the intellectual property protection based on the patent, and is hopeful to enter the mainstream medicine market with medicine identity.
Along with the continuous improvement of medical level and the change of human living environment and life style, the human disease spectrum is obviously changed, chronic diseases, especially multi-organ diseases, low functions and other diseases caused by aging are increased, the incidence rate of diseases and some cancers related to life style is obviously increased, mental diseases such as nerves and psychological disorders are increased, and important epidemic situations such as AIDS, SARS, avian influenza and new coronavirus infection bring great threat to human life safety.
4. The medical mode and the medical target are changed in response to the change of the disease spectrum. The medical mode changes from biomedical science mainly treating diseases to the combination of prevention, treatment, health care and rehabilitation, and the medical target changes to the integral and comprehensive treatment of diseases, prolongs the life expectancy of health and improves the life quality. The large health age presents new challenges for drug development, requires targeted treatment of patient population, timely prevention and recovery of sub-health population, and management and maintenance of health population. More targeted drugs, such as chronic drugs, drugs of major infectious diseases, personalized therapeutic drugs, and drugs that adapt to the state of economic development, are developed.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (10)
1. The compound Chinese medicine for resisting inflammation and clearing lung-heat is characterized by comprising the following raw materials:
abelmoschus manihot, honeysuckle, rhizoma atractylodis, astragalus mongholicus and liquorice.
2. The compound traditional Chinese medicine for resisting inflammation and clearing lung-heat, according to claim 1, is characterized in that the mass ratio of the abelmoschus manihot to the honeysuckle to the rhizoma atractylodis to the astragalus membranaceus to the liquorice is 5-7:2-2.5:2-2.5:1-1.5:1-1.5.
3. The abelmoschus manihot compound anti-inflammatory lung-heat clearing traditional Chinese medicine according to claim 1, wherein the preparation method of the abelmoschus manihot compound anti-inflammatory lung-heat clearing traditional Chinese medicine is as follows:
mixing the abelmoschus manihot, honeysuckle, rhizoma atractylodis, astragalus mongholicus and liquorice with a solvent, and extracting to obtain an extracting solution;
concentrating the extracting solution to obtain concentrated solution;
drying the concentrated solution to obtain extract dry powder;
mixing the extract dry powder with auxiliary materials and adhesive, and granulating to obtain wet granules;
and drying the wet granules to obtain dried granules, wherein the dried granules are the abelmoschus manihot compound traditional Chinese medicine for resisting inflammation and clearing lung.
4. The compound Chinese medicine for resisting inflammation and clearing lung-heat according to claim 3, wherein the density of the concentrated solution is 1.1-1.2.
5. The compound traditional Chinese medicine for resisting inflammation and clearing lung-heat according to claim 3, wherein the moisture content of the dried particles is less than 5%.
6. The abelmoschus manihot compound anti-inflammatory lung-heat-clearing traditional Chinese medicine according to claim 3, wherein the auxiliary materials are dextrin and lactose.
7. The compound traditional Chinese medicine for resisting inflammation and clearing lung-heat according to claim 3, wherein when the extract is obtained by mixing the abelmoschus manihot, honeysuckle, rhizoma atractylodis, astragalus membranaceus and liquorice with a solvent, the method comprises the following steps:
mixing the flos Abelmoschi Manihot, flos Lonicerae, rhizoma Atractylodis, radix astragali, glycyrrhrizae radix with solvent, heating with steam, and maintaining at 60-100deg.C for 1-2 hr to obtain the extractive solution.
8. The compound traditional Chinese medicine for resisting inflammation and clearing lung-heat according to claim 7, wherein the addition amount of the solvent is 8-10 times of the total weight of the abelmoschus manihot, honeysuckle, rhizoma atractylodis, astragalus and liquorice.
9. The compound Chinese medicine for resisting inflammation and clearing lung-heat according to claim 3, wherein the solvent is water or alcohol.
10. The compound Chinese medicine for resisting inflammation and clearing lung-heat according to claim 9, wherein the concentration of the alcohol is 40-80%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311836548.5A CN117695327A (en) | 2023-12-28 | 2023-12-28 | Abelmoschus manihot compound anti-inflammatory lung-heat-clearing traditional Chinese medicine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311836548.5A CN117695327A (en) | 2023-12-28 | 2023-12-28 | Abelmoschus manihot compound anti-inflammatory lung-heat-clearing traditional Chinese medicine and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117695327A true CN117695327A (en) | 2024-03-15 |
Family
ID=90160734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311836548.5A Pending CN117695327A (en) | 2023-12-28 | 2023-12-28 | Abelmoschus manihot compound anti-inflammatory lung-heat-clearing traditional Chinese medicine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117695327A (en) |
-
2023
- 2023-12-28 CN CN202311836548.5A patent/CN117695327A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105560372A (en) | Traditional Chinese medicine spray for treating rhinitis and preparation method thereof | |
| CN104642698A (en) | Candy capable of clearing heat, relieving sore-throat and detoxifying | |
| CN103239662B (en) | Parasite expelling Chinese herbal preparation for animals | |
| CN108938716A (en) | A kind of thoat-soothing drops and preparation method thereof containing licorice | |
| CN103202981B (en) | Medicine for treating trauma infectious diseases of animals | |
| CN104983968B (en) | Antipyretic traditional Chinese medicine composition and preparation method thereof | |
| CN104474404A (en) | Compound suppositorycontrollinginfectionof immunodeficiency patient | |
| CN103845616A (en) | Pharmaceutical composition for eliminating inflammation and disinfecting | |
| CN117695327A (en) | Abelmoschus manihot compound anti-inflammatory lung-heat-clearing traditional Chinese medicine and preparation method thereof | |
| CN100402073C (en) | Medicine for treating disease caused by heat toxin | |
| CN107638478B (en) | Yao medicine external preparation for treating skin diseases and preparation method thereof | |
| CN111632080A (en) | Formula for treating drug eruption dermatitis, preparation method and application | |
| CN105055657A (en) | Spraying agent for improving pain caused by wisdom teeth and preparation method thereof | |
| CN110946900A (en) | Qi-tonifying cold-dispelling decoction for allergic rhinitis | |
| CN104940419A (en) | Traditional Chinese medicine capable of preventing colds and allergies and enhancing immunity | |
| CN105168496B (en) | A kind of Chinese traditional medicine composition and preparation method preventing and treating Duck Hepatitis Virus | |
| CN103705599B (en) | A kind of pharmaceutical composition for the treatment of cough and preparation method thereof | |
| CN102688385B (en) | Traditional Chinese medicine for curing intermediate and terminal cancer | |
| CN104186870A (en) | Internal heat-reducing healthy tea | |
| CN106692698B (en) | Bletilla striata cough relieving granule and preparation method thereof | |
| CN104547464A (en) | Traditional Chinese medicine decoction for treating upper respiratory infection and preparation method of traditional Chinese medicine decoction | |
| CN114568568A (en) | Herbal tea containing scutellaria baicalensis leaves and preparation method | |
| CN104491331B (en) | A kind of pharmaceutical composition with antitussive action | |
| CN112370495A (en) | Electuary for treating oral ulcer and preparation method thereof | |
| CN113350475A (en) | Pungent and warm exterior syndrome relieving cold composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |